Glenmark unit clinches $700mn licensing deal for its cancer drug

The deal also entails $1.23 billion in milestone payments. While Glenmark unit IGI will retain rights for India and emerging markets, AbbVie will develop and market ISB 2001 in North America, Europe, Japan, and Greater China